Comparative risk of major bleeding with new oral anticoagulants (NOACs) and Phenprocoumon in patients with atrial fibrillation – effectiveness analyses added (CARBOS E+)

Study identification

• EU PAS number:
  EUPAS18323
• Study ID:
  22064
• Official title and acronym:
  Comparative risk of major bleeding with new oral anticoagulants (NOACs) and Phenprocoumon in patients with atrial fibrillation – effectiveness analyses added (CARBOS E+)
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study status:
  Finalised

Research institutions and networks

Institutions

N/A

Study timelines

Date when funding contract was signed

Planned: 31/10/2016

Actual: 31/10/2016

Study start date

Planned: 13/04/2017

Actual: 13/04/2017

Data analysis start date

Planned: 02/05/2017

Date of final study report

Planned: 31/10/2017

Actual: 19/12/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer and Bristol-Myers Squibb

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable